First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer

on

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany GmbH will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.

Based on a manufacturing agreement to be negotiated, the plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry™, an antihemophilic factor (recombinant). The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions. Financial details were not disclosed.

“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high quality drug product manufacturing capacities and capabilities,” said Dr. Chris Chen, CEO of WuXi Biologics. “Our business in EU, US and China market has experienced robust growth in the past few years. This additional drug product plant further confirms our commitment to ‘Global Dual Sourcing within WuXi Biologics’ strategy. WuXi Biologics will continue to expand our worldwide capacity, providing global partners with a robust and premier-quality supply chain network to benefit patients worldwide.”

About WuXi Biologics 

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network.

 

If you like this article, please help us by making a donation so that we can continue our work. Please help keep us independent.

 

Subscribe to China Underground and get Planet China

To be updated with all the latest news, offers and special announcements. Planet China is a free digital magazine including interviews with experts, directors, designers, photographers, journalists, critics, and artists.

China-Underground
China-Undergroundhttp://china-underground.com
CinaOggi.it and China-underground.com are two websites focused on China and Chinese culture. The site includes thousands of articles on this country structured in categories: news, trends, economy, history, art, guides, literature , pictures gallery, videos and Chinese cinema.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search

2,079FansLike
1,175FollowersFollow
305SubscribersSubscribe

Latest

Tokyo Takes Top Destinations Spot for Asian Travelers During Lunar New Year 2020

Tokyo Takes Top Destinations Spot for Asian Travelers During Lunar New...

0
Tokyo, Bangkok and Taipei are the top three destinations for travelers from across Asia to celebrate the Lunar New Year, according to...
 

If you like this article, please help us by making a donation so that we can continue our work. Please help keep us independent.